Back to results
US 2007/0184501 A1Published application
Blocker reagent for reduction of heterophile interferences
AssigneeBeckman Coulter, Inc.
InventorBruce Odegaard
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeBeckman Coulter, Inc.
InventorBruce Odegaard
Estimating the term…
A specific blocking reagent, method of manufacture thereof and methods of use are provided. The blocking reagent uses the specific antibody structure recognized by the target, e.g., analyte, and any interfering substances, e.g., heterophile molecules. The blocking reagent is, however, an inactivated form of the target-specific antibody. Thus, the blocking reagent cannot bind the target because the target-binding regions have been inactivated. The blocking reagent can, however, block interfering substances such as heterophile molecules as these binding regions remain active. In this manner, the blocking reagent provides highly specific removal of interferents. The blocking reagent thus has broad applicability in immunoassays as well as enhanced delivery of therapeutic and/or diagnostic agents.
An immunoassay reagent system to qualitatively or quantitatively analyze at least one analyte in a test sample that might contain heterophile interferents, comprising:
A blocker reagent comprising an inactivated form of a target-specific antibody for use in reducing interference of the binding of a target analyte with the target-specific antibody or from the formation of a complex that would be formed in the absence of the target analyte causing a false positive result.
An immunoassay method for quantitatively or qualitatively analyzing at least one analyte in a test sample that may contain heterophilic interferents, comprising:
A method of manufacturing a heterophile interferent blocker reagent for use in an immunoassay reagent system, comprising:
A method for improving delivery of at least one agent to a target in a subject, wherein at least one interfering substance interferes with delivery of the at least one agent to the target, comprising:
A pharmaceutical composition, the composition having a target, comprising:
Dependencies are inferred from the claim text.